SK Acquires AMPAC, On Track To Meet Global Contract Manufacturing Ambitions
With the acquisition of US-based contract development and manufacturing organization AMPAC Fine Chemicals, SK has added the US production base to its European and Korean production facilities, placing it on track to becoming a top global CDMO player with annual production capacity of about 1.6 million liters.
You may also be interested in...
From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.
Merger and acquisition deals in South Korea’s pharma/biotech sector have remained relatively few compared to other countries, but several factors are now pointing to a possible increase in activity as pharma and biotech firms hunt for new technologies and growth.
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.